Endoscopic approach and stereotactic radiosurgery for a posterior third ventricular Central Neurocytoma – case report and literature review

Jolyn Kho*, Gert Tollesson

Neurosurgery, Greenslopes Private Hospital, Newdegate Street, Greenslopes, QLD 4120, Australia

**ABSTRACT**

**INTRODUCTION:** Central Neurocytomas (CN) are a rare intracranial tumour, most often arising in the lateral ventricles and presenting with obstructive hydrocephalus. Isolated lesions in the third ventricle are uncommon. We present the fourth reported case of posterior third ventricular CN successfully managed surgically via endoscopy, allowing for concurrent biopsy and therapeutic endoscopic third ventriculostomy (ETV). Stereotactic radiosurgery was administered for the residual lesion. A brief review of CNs and previous similar cases is also provided.

**PRESENTATION OF CASE:** A 58-year-old male presented with progressive decline in cognition and gait. Subsequent Magnetic Resonance Imaging revealed obstructive hydrocephalus secondary to a posterior third ventricular lesion. An endoscopic biopsy and concurrent cerebrospinal fluid diversion by ETV was performed. Pathological analysis was consistent with a CN with positivity to Synaptophysin. MIB-1 proliferation index was 1%. There was good clinical recovery, and the patient underwent adjuvant stereotactic radiosurgery 1.5 months post-surgery.

**DISCUSSION:** Due to the rarity of CNs arising from the third ventricle, there are only three previous reports of these approached endoscopically. Such a technique allows for good visualisation of the lesion, and therapeutic ETV to relieve obstructive hydrocephalus. This case supports this approach as a valid, minimally invasive option. Additionally, this is the first case to report the MIB-1 proliferation index, contributing to future outcome evaluation of endoscopic approaches to typical (MIB-1 < 2%) versus atypical (MIB-1 > 2%) CNs.

**CONCLUSION:** Endoscopic biopsy with concurrent ETV and adjuvant stereotactic radiosurgery is a valid treatment option for deep seated isolated small posterior third ventricular CNs.

© 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Central Neurocytomas (CN) are a rare form of intracranial neoplasm, accounting for 0.1–0.5% of cases with peak incidence between 20–40 years of age. Lesions are typically located in the anterior half of the lateral ventricles, with attachment to the septum pellucidum [1,2]. CNs arising from the third or fourth ventricles are even more uncommon [3]. Due to compounded rarity of isolated third ventricular CNs, there is limited literature guiding management of these. In line with SCARE guidelines [4], we present a case of a posterior third ventricular CN with MIB-1 proliferation index 1% that was surgically biopsied via an endoscopic approach with concurrent endoscopic third ventriculostomy (ETV), and adjuvant radiosurgery for residual disease. The endoscopic technique has only been used in three other previous cases of posterior third ventricular CNs [5–7], but none with documented proliferation indexes. We review the previous similar cases, and current literature regarding the management of CNs. We also briefly review two previous reports of CNs located just adjacent to the third ventricle that were also managed endoscopically [8].

2. Presentation of case

A 58-year-old male presented to the emergency department with progressive decline in cognition and gait with recurrent falls over days, on a background of generalised lethargy for 3–4 months. There was a sight headache but no nausea. Past medical history was significant only for asthma, with no regular medications. Clinically the patient had a Glasgow Coma Score of 15, though there was a
slowness of thinking below baseline. He had a wide based unsteady gait, but no other focal neurology.

A Computed Tomography scan of the brain was significant for triventriculomegaly with no obvious lesion. Subsequent Magnetic Resonance Imaging (MRI) brain revealed a 7 mm round lesion in the posterior third ventricle obstructing the aqueduct. It was hyperintense on T2 and FLAIR, and hypointense on T1 with no contrast enhancement (Fig. 1). The lesion extended along the left periaqueduct to the superior fourth ventricle (Fig. 2). Obstructive hydrocephalus with transependymal flow was also demonstrated (Fig. 1).

Given the deep-seated location and the resultant obstructive hydrocephalus, an endoscopic approach was planned to allow for both an ETV and endoscopic biopsy. Under navigation guidance, a standard ETV was performed via a fronto-burr hole with balloon fenestration. A second, more anterior right burr hole was required to achieve the trajectory needed to reach the lesion. Intraoperatively, the lesion appeared as a pinkish, friable mass just anterior to the opening of the cerebral aqueduct. Biopsy samples were obtained using rongers. As the lesion extended periaqueductally towards the fourth ventricle, gross total resection (GTR) could not be attempted safely.

Post operatively, the patient noticed a marked improvement in cognition and gait. A day one brain MRI with cerebrospinal fluid (CSF) flow studies confirmed a patent ETV, with a reduction in the degree of hydrocephalus. The lesion itself appeared similar.

Histological analysis of the tumour showed mild increase in cellularity with rosetting, but no high-grade features on standard Haematoxylin and Eosin (H&E) stain. Immunohistochemistry was moderately positive for Synaptophysin (Fig. 3) and positive for Oligo 2, with variable staining for Glial fibrillary acid protein (GFAP). Epithelial membrane antigen (EMA) was negative and there is diffuse positivity for S-100. Both IDH 1R132H and P53 were negative. The MB-1 index was 1%. Fluorescence in situ Hybridization was negative for both 1P 19Q co-deletion and Epidermal Growth Factor Receptor amplification. These findings were most in keeping with a diagnosis of CN.

A 1 month MRI brain and spine showed ongoing ETV patency with a further reduction in hydrocephalus. The lesion was unchanged, and there was no spinal metastasis. The patient underwent stereotactic radiosurgery with 29 Gy in 5# to the residual lesion 1.5 months after surgery. At 5 months post operation, MRI brain demonstrated a decrease in size of the lesion with new rim enhancement reflecting treatment effect. The ETV remained patent and there was resolution of hydrocephalus (Fig. 4). The patient returned to work uneventfully and remained clinically well at 5 months post operation.

3. Discussion

CNs were first proposed as a distinct tumour type by Hassoun et al. in 1982 [9], and are considered a benign neoplasm with a grade two classification by the World Health Organisation [1,2]. CNs are very rare, making up only 0.1–0.5% of central nervous system tumours, and peak incidence is between 20–40 years of age [1,2]. Lesions typically arise from the lateral ventricles, and may extend into the distal ventricles. Isolated origin from the third or fourth ventricle is less common [3]. Clinically, patients may present with obstructive hydrocephalus, most frequently from blockage of the Foramen of Monro for typically located tumours [1,2].

Histopathologically, CNs can resemble oligodendrogliomas or ependymomas under light microscope with standard stains, making diagnosis complex. Immunohistochemistry is generally required to guide diagnosis, though it is recognised that markers can have cross-positivity with other tumours and more research is required to develop diagnostic accuracy [1,2]. Positivity for synaptophysin is considered the main marker for CNs, and negative testing for EMA, vimentin and neuron specific enolase support CN over oligodendrogliomas and ependymomas. GFAP is usually absent in CNs, however cases of positive results have been reported before suggesting a precursor cell with differential bipotential towards both glial and neuronal [1,2]. Neuron-specific nuclear protein is more likely to be positive in CNs than oligodendrogliomas [2,10], while the converse is found for Oligo2 [1,10]. The MIB-1 proliferation index is considered an important prognostic indicator in CNs where patients with an index >2% have a higher chance of recurrence and lower survival at 10 years. It has been proposed that CNs with an index >2% be considered ‘atypical’ and more aggressive, and have been found to metastasize along the neural axis [1,11,12].

The mainstay management of CNs involves GTR. An analysis of 438 patients by Rades and Schild [13] found that for both typical and atypical lesions, patients with GTR had significant improvement in survival and local control when compared to subtotal resection (STR) alone. Adjuvant radiotherapy is advocated for residual lesions in STR, and significantly bettered outcomes of survival and local control. The use of adjuvant stereotactic radiosurgery for STR has also been reported, and may potentially be more effective than fractionated radiotherapy with a trend towards better survival and local control rates, though this did not reach statistical significance [14].

Lesions of the posterior third ventricle are deep and challenging to reach surgically. Small lesions are amenable to an endoscopic approach which allows for minimal access surgery, good visualisation of the lesion, and ability to perform concurrent CSF diversion via an ETV. Due to the rarity of CNs, and its unlikelihood to arise from the third ventricle, there are only three previous reports where endoscopic technique was utilised for management of isolated third ventricular CNs (Table 1) [5–7]. Of note, an additional two cases of CNs located just adjacent to the posterior third ventricle have likewise been successfully managed with this approach [8].

Javedan et al. [5] were the first to introduce this technique in a 54-year-old patient with obstructive hydrocephalus from a posterior third ventricular CN. Endoscopic biopsy of the lesion was undertaken but adherence to the surrounding tissue and vessels prevented more extensive debulking. An ETV was also performed, and the patient underwent adjuvant stereotactic radiosurgery of the residual tumour two weeks later. There was good clinical recovery, and a 25-month follow-up MRI showed minimal decrease of the lesion, a patent ETV, and resolution of the hydrocephalus. The authors did not mention the MIB-1 proliferation index.

Park et al. [6] describe on a 79-year-old female with a multilobulated 1.8 cm posterior third ventricular CN also presenting with obstructive hydrocephalus. Similarly, an ETV was performed along with endoscopic biopsy of the lesion. Adjuvant stereotactic radiosurgery was undertaken at one week post-surgery, and a 3–month progress MRI show a decrease in the lesion size to 1.4 cm with the patient remaining well at 8 months. It was suggested that stereotactic radiosurgery could be a suitable treatment alternative to deeply seated CNs in older patients. Unfortunately, the MIB-1 proliferation index was also not reported.

In the report by Romano et al. [7] a 37-year-old female presented with obstructive hydrocephalus and left abducens nerve palsy secondary to a posterior third ventricular CN. With the aid of a diode laser and rongeur via an endoscopic technique, GTR of the lesion was achieved and an ETV was also performed. The patient did well postoperatively with resolution of the diplopia. There was no adjuvant radiotherapy or radiosurgery, and subsequent post-operative MRIs up to 36 months did not show any residual or regrowth of the CN. This was the only reported case where GTR was attained, with
the use of a diode laser instrumental to achieving this safely. The MIB-1 proliferation index was not mentioned.

A side noteworthy paper to mention is by Gomes et al. [8] where two cases of CNs located just adjacent to the third ventricle were similarly managed endoscopically. A 58-year-old male with a pineal region lesion, and a 21-year-old female with an aqueductal region lesion both presented with symptoms of obstructive hydrocephalus, and underwent endoscopic biopsy along with ETV. Post-operative resolution of the hydrocephalus and good clinical outcomes were achieved, and no adjuvant radiotherapy or radiosurgery was given. Neither case had the MIB-1 proliferation index reported. The authors emphasized that CNs in the pineal and aqueductal regions appear similar to tectal gliomas, and can be successfully approached endoscopically.

This current case report represents the fourth reported successful usage of endoscopic approach for a small posterior third ventricular CN and CSF diversion by an ETV. Because the lesion extended down the left periaqueduct to the superior fourth ven-

Fig. 1. MRI brain showing: A - Sagittal T2 sequence with posterior third ventricular lesion obstructing aqueduct (arrow); B - Same lesion (arrow) appearing hypointense and non-enhancing on sagittal T1 with contrast sequence; C - Axial FLAIR sequence with lesion appearing hyperintense (red arrow). Obstructive hydrocephalus with prominent temporal horns and transependymal flow (white arrows).

Fig. 2. MRI brain axial FLAIR sequences showing tumour extension along left periaqueduct (arrows).
tricle, GTR was not achievable. The patient underwent adjuvant radiosurgery of the residual lesion as recommended in previous reviews of this rare tumour. Of the four reports, this is the only case to have a documented MIB-1 proliferation index, which will contribute to future evaluation of endoscopic approaches for typical versus atypical posterior third ventricular CNs. Consideration of use of a diode laser to aid endoscopic resection was felt as an important learning point from the review of previous cases, though this is operator dependent and requires technical training.
This references

Jolyn Khoo – Primary author.
Gert Tollesson – Reviewer.

N/A.

Jolyn Khoo.

Not commissioned, externally peer-reviewed.

None.

[1] S. Lee, T. Bui, C. Chen, C. Lagman, L. Chung, S. Sidhu, et al., Central neurocytoma: a review of clinical management and histopathologic features, Brain Tumor Res. Treat. 4 (2) (2016) 49–57, http://dx.doi.org/10.14791/btrt.2016.4.2.49.

[2] D. Patel, R. Schmidt, J. Liu, Update on the diagnosis, pathogenesis, and treatments strategies for central neurocytoma, J. Clin. Neurosci. 20 (2013) 1193–1199, http://dx.doi.org/10.1016/j.jocn.2013.01.001.

[3] J. Wong, C. Teo, B. Kwock, Central neurocytoma in third and fourth ventricle with aqueductal involvement, Br. J. Neurosurg. 20 (1) (2006) 57–62, http://dx.doi.org/10.1080/02688690600598463.

[4] R.A. Agha, M.R. Borrelli, R. Farwana, K. Koshy, A. Fowler, D.P. Orgill, For the SCARE Group, The SCARE 2018 statement: updating consensus surgical Case Report (SCARE) guidelines, Int. J. Surg. 60 (2018) 132–136.

[5] S. Javedan, K. Manwaring, K. Smith, Treatment of posterior third ventricular central neurocytoma with endoscopic biopsy, endoscopic third ventriculostomy, and stereotactic radiosurgery. Minimally Invasive Neurosurg. 46 (3) (2003) 165–168, http://dx.doi.org/10.1055/s-2003-40744.

[6] S. Park, T. Jung, S. Kim, K. Lee, Tumor control of third ventricular central neurocytoma after gamma knife radiosurgery in an elderly patient, Medicine 97 (2018) 50, http://dx.doi.org/10.1097/MD.00000000000013657.

[7] A. Romano, S. Chibbaro, O. Makise, M. Marsella, P. Mainini, E. Benericetti, Endoscopic removal of a central neurocytoma from the posterior third ventricle, J. Clin. Neurosci. 16 (2009) 312–316, http://dx.doi.org/10.1016/j.jocn.2008.03.011.

[8] F. Gomes, L. Franca, S. Zymbarg, S. Cavalheiro, Central neurocytomas of uncommon locations, report of two cases, Arq. Neuropsiquiatr. 64 (4) (2006) 1015–1018.

[9] J. Hassoun, D. Gambarelli, F. Grisoli, W. Pellet, G. Salamon, F. Pellissier, et al., Central neurocytoma, an electron-microscopic study of two cases, Acta Neuropathol. 56 (1982) 151–156.

[10] X. Xiao, J. Zhou, J. Wang, L. Yang, C. Wang, Y. Xu, et al., Clinical, radiological, pathological and prognostic aspects of intraventricular oligodendroglioma: comparison with central neurocytoma. J. Neurooncol. 135 (1) (2017) 57–65, http://dx.doi.org/10.1007/s11060-017-2490-0.

[11] G. Vajrala, P. Jain, S. Shitalkumar, S. Madigubba, S. Immaneni, M. Panigrahi, Atypical neurocytoma: dilemma in diagnosis and management, Surg. Neurol. Int. 5 (2014) 183, http://dx.doi.org/10.4103/2152-7666.147414.

[12] P. Mozes, E. Szanto, L. Tiszlavec, P. Barzo, A. Cserhati, E. Fodor, et al., Clinical course of central neurocytoma with malignant transformation: an indication for craniospinal irradiation, Pathol. Onclol. Res. 20 (2014) 319–325, http://dx.doi.org/10.1007/s12253-013-9697-y.

[13] D. Rades, E. Schilt, Treatment recommendations for the various subgroups of neurocytomas. J. Neurooncol. 77 (2006) 305–309, http://dx.doi.org/10.1007/s11060-005-9047-2.

[14] R. García, M. Ivan, T. Oh, I. Barani, A. Parsa, Intraventricular neurocytoma: a systemic review of stereotactic radiosurgery and fractionated conventional radiotherapy for residual or recurrent tumors, Clin. Neurol. Neurosurg. 117 (2014) 55–64, http://dx.doi.org/10.1016/j.clineuro.2013.11.028.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the JJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.